Roche, Xenon ink $646 million pain pact
Xenon will receive an undisclosed upfront payment from Genentech, as well as research funding. Xenon has the possibility of receiving additional R&D commercialization milestone payments of up to $646 million, plus royalties. In return, Genentech will have an exclusive license to compounds and a non-exclusive right to any diagnostics.
This alliance is Xenon’s sixth partnership with a major pharmaceutical company, including Merck, Takeda and Novartis.